How clinical trials turn research into real-world care

Progress in prostate cancer research doesn’t happen in a single leap. It happens step by step, starting with an idea, moving through careful investigation, and ending with better tests, kinder treatments and longer lives.

Clinical trials are a key stage on that journey. And they’re made possible by people like you – from taking part in the trial itself, to supporting our work through volunteering, donating or fundraising.

Here’s how your support helps a prostate cancer research trial move from idea to impact.

Turning an idea into a real-world plan

Every trial begins with a question.

"Could this new scan spot aggressive prostate cancer earlier?"

"Could this treatment control the disease with fewer side effects?"

"Could this test reduce unnecessary biopsies, or avoid treatment men don’t need?"

Researchers spend years developing these ideas in the lab, working to understand the biology of the disease and how it might behave in response to a new treatment or how a new test might reveal additional information about the cancer. Your support helps us to fund this research, in labs across the country.

But to make a difference to men, those ideas must be tested safely with real people in real life situations. That’s where clinical trials come in.

Clinical trials are research studies that involve men with, or at risk of, prostate cancer. They aim to find out whether we can diagnose or treat prostate cancer better than we can now.  

Building a fair and reliable trial

When we’re considering whether to fund a trial, we look at whether it’s designed to give clear and reliable answers that men and their doctors can trust.

A high-quality trial is usually randomised, blinded, and compared against the current best approach. These steps help researchers work out as fairly and accurately as possible whether a new test or treatment is genuinely helping men.

• In a randomised trial, men are put into different groups by chance, not by choice. This helps make the groups as similar as possible, so if one group does better, researchers can be more confident it’s because of the test or treatment itself.

• In a blinded trial, men, and sometimes the research team, don’t know who’ll get which treatment. This is important because expectations can affect how people report symptoms, side effects or improvements. Blinding helps keep the results as objective as possible.

• New approaches are compared with the current standard treatment. This shows whether the new approach is actually better than what’s already available, or whether any benefit might simply have happened anyway.

This careful groundwork takes time, expertise and resources, but it’s vital to the process. It helps ensure that when a trial shows promise, it’s not just by chance. 

Along the diagnostic pathway

Not every man will take part in a trial. But every man can benefit from one.

The pathway we use to diagnose and treat prostate cancer today – PSA testing, mpMRI scans, targeted biopsies and more tailored treatments – has been shaped by past trials.

For example, we helped to fund research that showed having mpMRI scans before a biopsy could safely rule out many biopsies as unnecessary.

We also supported the research that led to olaparib becoming the world’s first precision medicine for prostate cancer.

Clinical trials like these have revolutionised how men are diagnosed and treated, saving and improving the lives of thousands of men every year.  

And, in the same way, tomorrow’s diagnostic pathway will be shaped by the trials you help fund today, such as our TRANSFORM screening trial. 

A phased approach

These new treatments and procedures are tested in phases, each one moving the science forward with care.

Early‑phase trials ask: Is this safe? What dose works best? What side effects should we expect?

Later‑phase trials ask: Is this better than what men already receive? Does it improve survival or quality of life?

By the time we reach a phase III trial, hundreds or thousands of men may be involved. Their participation helps researchers understand whether a new approach truly deserves a place in everyday care.

Your support keeps this journey moving, from cautious first steps to confident strides toward better options for men.

Gathering evidence that changes practice

Clinical trials don’t end when the last man finishes treatment.

Researchers pore over the data, collected over months or years, analysing outcomes, side effects, quality of life and long‑term results.

Sometimes they’ll even continue studying the impact of a treatment after it becomes available on the NHS, to see if they can find an even better, more effective way to offer it to men.

If all this data shows that something works better, more safely, or with fewer side effects, that evidence can shape the way doctors diagnose and treat prostate cancer, both in the UK and worldwide.

Sometimes the impact is immediate. Sometimes it takes time. But each trial adds another step along the path toward better care, and another moment where you can help move prostate cancer research – and men – in the right direction.

Together, we can power these improvements.

Donate today to help fund life-changing research that will give every man the power to navigate prostate cancer.

Thank you.

Donate now